MiR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor

Biomedicine and Pharmacotherapy

Volumn 72, Issue , 2015, Pages 158-164

  Wei, Renxiong ^a   Deng, Zhouming ^a   Su, Jiajia ^b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI CANCER HOSPITAL   (China)

Author keywords

MiR 217; Osteosarcoma; Tumor progression; Wnt5a

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA; MICRORNA 217; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; WNT5A PROTEIN; MIRN217 MICRORNA, HUMAN; ONCOPROTEIN; WNT PROTEIN; WNT5A PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER MORTALITY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; U2OS CELL LINE; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; WNT PROTEINS;

EID: 84930518686     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.04.012     Document Type: Article

References (22)

1. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115(7):1531-1543.
2. Osborne T.S., Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J. Comp. Pathol. 2012, 146(2-3):132-142.
3. Posthuma De Boer J., Witlox M.A., Kaspers G.J., van Royen B.J. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin. Exp. Metastasis 2011, 28(5):493-503.
4. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., Roth S.I., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008, 22(12):1662-1676.
5. Oom A.L., Humphries B.A., Yang C. MicroRNAs: novel players in cancer diagnosis and therapies. Biomed. Res. Int. 2014, 2014:959461.
6. Hayes J., Peruzzi P.P., Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 2014, 20(8):460-469.
7. Nugent M. MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag. Res. 2014, 6:15-25.
8. Ell B., Kang Y. MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep. 2014, 3:549.
9. Li H., Zhao J., Zhang J.W., Huang Q.Y., Huang J.Z., Chi L.S., et al. MicroRNA-217, down-regulated in clear cell renal cell carcinoma and associated with lower survival, suppresses cell proliferation and migration. Neoplasma 2013, 60(5):511-515.
10. van Rooij E., Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 2014, 6(7):851-864.
11. Xia H., Ooi L.L., Hui K.M. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013, 58(2):629-641.
12. Zhao W.G., Yu S.N., Lu Z.H., Ma Y.H., Gu Y.M., Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 2010, 31(10):1726-1733.
13. Enomoto M., Hayakawa S., Itsukushima S., Ren D.Y., Matsuo M., Tamada K., et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 2009, 28(36):3197-3208.
14. ® platform. BMC Med. Genomics 2010, 3:60.
15. Ren D., Minami Y., Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells 2011, 16(3):304-315.
16. Yamagata K., Li X., Ikegaki S., Oneyama C., Okada M., Nishita M., et al. Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression. J. Biol. Chem. 2012, 287(2):1588-1599.
17. Lu B.J., Wang Y.Q., Wei X.J., Rong L.Q., Wei D., Yan C.M., et al. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol. Med. Rep. 2012, 5(4):1033-1036.
18. Jin Z., Zhao C., Han X., Han Y. Wnt5a promotes Ewing sarcoma cell migration through upregulating CXCR4 expression. BMC Cancer 2012, 12:480.
19. Sharili A.S., Allen S., Smith K., Price J., McGonnell I.M. Snail2 promotes osteosarcoma cell motility through remodelling of the actin cytoskeleton and regulates tumor development. Cancer Lett. 2013, 333(2):170-179.
20. Brun J., Dieudonné F.X., Marty C., Müller J., Schüle R., Patiño-García A., et al. FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS One 2013, 8(1):e55034.
21. Zhang A., He S., Sun X., Ding L., Bao X., Wang N. Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals. Cancer Cell Int. 2014, 14(1):15.
22. Enomoto M., Hayakawa S., Itsukushima S., Ren D.Y., Matsuo M., Tamada K., et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 2009, 28(36):3197-3208.